veNTIlATIoN - Green Cross Publishing

More documents

Recommendations

Info

news 6 older people urged to look after their mental health As we are in the winter months older people in Ireland are being encouraged to look after their mental health and to seek help and support if they are feeling depressed most of the day, most days. Leading Old Age Psychiatrist, Professor Brian Lawlor, and advocacy group Age Action urged older people to address the issue of their mental health at the launch of the ‘Mind Yourself — Depression in Later Life’ leaflet recently. The leaflet, produced by Lundbeck (Ireland) Ltd, provides useful information to help people recognise the symptoms of depression in later life and how to access support services and resources. The leaflet was developed following research amongst over 65 year olds, carried out by Behaviour and Attitudes on behalf of Lundbeck which shows that almost 60% of those surveyed believe that people in their age group would be reluctant to discuss depression with others. One quarter of respondents said they believed that depression is a state of mind and not an illness which could indicate a lack of understanding of depression, resulting in many older people with depression not being diagnosed or receiving the help they need. Some 91% of respondents believed that depression can have a very negative impact on a person’s life, with 82% believing that depression is not well understood by many people. Well over two thirds (70%) of those with depression think that there is a lot or some social stigma associated with depression. Irish pharmaceutical contract sales organisations (CSO) Pharmexx Ireland Ltd and Alchemy Healthcare (Ireland) Ltd have now merged. The new company, Pharmexx Alchemy, will have a 15% market share in the Irish pharmaceutical CSO market, which is estimated to be worth €20 million overall. The company provides outsourcing of skilled pharmaceutical and retail representatives to most of the leading pharmaceutical companies based in Ireland. It also offers specialised nursebased patient support programmes, as well as more traditional contract sales. Pharmexx Alchemy has set forth an ambitious model for growth, with an aim to become the number-one player in the CSO market by 2015. Pharmexx Ireland and Alchemy both started business in 2008. Pharmexx, part of the international Pharmexx group (owned by German company Celesio, which is also represented in Ireland by Cahill May Roberts, Movianto and Unicare), offers integrated commercialisation services by combining warehousing and special logistics services with CSO solutions for a broad range of pharmaceuticals. Alchemy Healthcare, led by founders and managers Mick O’Leary and Pat Kerley, provides a highly The research also revealed that those most likely to suffer from depression in this age group are older women who are widowed. “With older people, while their physical ailments may be detected and addressed their depression can often be overlooked and undertreated,” according to Professor Lawlor, “Factors such as social isolation, bereavement and retirement can be extremely distressing for older people and can lead to depression. I would urge people to look out for warning signs. Low mood or sadness, social withdrawal, increased fatigue, loss of appetite, disturbed sleep, loss of enjoyment, feelings of hopelessness or life not worth living can all point to the presence of depression and should not be ignored.” Eamon Timmins, Age Action welcomed the research saying, “This research gives us a valuable insight into the attitudes towards depression among the over 65s. Our ethos is to empower older people so that they can enjoy their later years. We would urge them to take account of their mental health as well as their physical health. Depression is not an inevitable part of ageing and can be treated successfully.” The new information leaflet, ‘Mind Yourself — Depression in Later Life”, is being launched today by Lundbeck (Ireland) Ltd to help older people who may have depression. It is available free by calling 01-468 9800 and will be distributed via GP surgeries. Pharmexx Ireland and Alchemy Healthcare merge to create Pharmexx Alchemy motivated management team with long standing experience and established contacts in the Irish pharmaceutical industry. Mick O’Leary, managing director of Pharmexx Alchemy, is confident that the range of services will appeal to the pharmaceutical market in Ireland; “Alchemy Healthcare built its success in the pharmaceutical market, supplying the best people and strategies to our clients, whilst Pharmexx has excelled in the retail/OTC space. The marriage of these two critical service areas will ensure a compelling business proposition for our existing and future clients. We look forward to providing the most integrated and complete range of services to the pharma industry in Ireland.” James Quinn, Commercial Director of Celesio Ireland, commented: “The newly created Pharmexx-Alchemy will allow Movianto to grow strongly in the CSO market. We have an ambitious goal of becoming the number-one player in Ireland by 2015. This merger is the first, important step in achieving this vision. The strengths of both these companies complement each other perfectly and provide an excellent platform for success.”
Butrans ® patches contain an opioid analgesic PRESCRIBING INFORMATION BuTrans ® 5µg/h, 10µg/h and 20µg/h Transdermal Patch Presentation: BuTrans 5µg/h, 10µg/h, 20µg/h. Transdermal beige patches containing buprenorphine. Indications: Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. BuTrans is not suitable for the treatment of acute pain. Dosage and Administration: BuTrans should be administered every 7 days. Elderly and adults over 18 years only: Use the 5 µg/h patch for at least the first 3 days of treatment, before increasing the dose if necessary. Do not use more than two patches at a time. Contra-indications: Known buprenorphine or excipient hypersensitivity, opioid dependent patients, narcotic withdrawal treatment, respiratory depression, us e of MAO inhibitors within the past 2 weeks, myasthenia gravis, delirium tremens, pregnancy and lactation. Precautions and Warnings: Convulsive disorders, head injury, shock, reduced consciousness of uncertain origin, intracranial lesions or increased intracranial pressure, severe hepatic impairment, history of drug abuse. Not recommended immediately postoperatively or for situations characterised by a narrow therapeutic index or for rapidly varying analgesic requirements. May ® Butrans is a Registered Trademark. © 2009 Napp Pharmaceuticals Limited. CODE 0924BTN. Date of item: April 2009 days pain relief in one BuTrans patch BuTrans® matrix patches are Ireland’s first patches designed to provide 7 days’ continuous relief from moderate osteoarthritis pain. Good news for doctors, good news for patients, good news for joints. affect ability to drive or use machinery. Interactions: Monoamine oxidase inhibitors (MAOIs), CNS depressants (e.g. benzodiazepines, opioid derivatives, antidepressants, sedatives, alcohol, anxiolytics, neuroleptics, clonidine). CYP 3A4 inhibitors and inducers, products reducing hepatic blood flow (e.g. halothane). Side Effects: Common: anorexia, confusion, depression, insomnia, nervousness, headache, dizziness, somnolence, paraesthesia, vasodilation, dyspnoea, constipation, dry mouth, nausea, vomiting, abdominal pain, diarrhoea, dyspepsia, sweating, tiredness, pain, peripheral oedema, application site reaction, chest pain, pruritus, erythema, rash, exanthema, asthenia. Potentially serious side effects also include: allergic reactions, psychotic disorder, hallucinations, nightmares, drug dependence, mood swings, dysarthria, migraine, syncope, visual disturbance, angina pectoris, palpitations, tachycardia, hypotension, hypertension, aggravated asthma, respiratory failure, diverticulitis, dysphagia, ileus, biliary colic, myalgia, depersonalisation, memory impairment, respiratory depression, urinary retention, decreased libido, pyrexia, rigors, alanine aminotransferase increased, drug withdrawal syndrome, abnormal coordination, circulatory collapse, wheezing. Please consult the SPC for details of other side-effects. Legal Category: CD (Sch2) POM. Package Quantities: 5 µg/h transdermal patch: 2 individually sealed patches. 10 µg/h transdermal patch: 4 individually sealed patches. 20 µg/h transdermal patch: 4 individually se aled patches. Marketing Authorisation Numbers: PA 913/24/1-3. Marketing 7 7 Days’ Days’ continuous continuous relief relief from from MODERATE MODERATE OSTEOARTHRITIS OSTEOARTHRITIS PAIN PAIN Not suitable for the treatment of acute pain. Authorisation Holder: Napp Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. Further information is available from: Mundipharma Pharmaceuticals Ltd, Millbank House, Arkle Road, Sandyford, Dublin 18. Tel: +353 (0)1 2063800. Member of the Mundipharma/Napp independent associated companies. Date of Preparation: February 2009. Adverse events should be reported to Mundipharma Pharmaceuticals Limited on (01) 206 3800 When non-opioid analgesics aren’t enough
Page 1 and 2: The Journal of the Irish Practice N
Page 3 and 4: Nurse Prescribing editorial It’s
Page 5 and 6: The Journal of the Irish Practice N
Page 7: First nurse prescribers in addictio
Page 11 and 12: Danone Actimel, an ally for the eld
Page 13 and 14: 112009PandemicInfluenza2377 Your Pa
Page 15 and 16: KIlKeNNy PATRICIA MCQUILLAN regiona
Page 17 and 18: During NIV the patient usually wear
Page 19 and 20: Abbreviated Prescribing Information
Page 21 and 22: 1. DeFronzo RA, et al. Diabetes Car
Page 23 and 24: clinical review NIcolA corNAlly msc
Page 25 and 26: A body
Page 28 and 29: in practice 26 Post natal sexual he
Page 30 and 31: in practice 28 parents should be en
Page 32 and 33: 30 study Theme 1 — PhysIcAl eFFec
Page 34 and 35: 32 study Theme 3: NormAlITy Moreove
Page 36 and 37: 34 interview When Netta Williams st
Page 38 and 39: probiotics 36 Part 4 deIrdre JordAN
Page 40 and 41: probiotics 38 immune cells. Further
Page 42 and 43: probiotics 40 ‘In addition, studi
Page 44 and 45: probiotics 42 references 1. Calder
Page 46 and 47: 44 patient’s perspective Fighting
Page 48 and 49: 46 poster series Foot care and foot
Page 50 and 51: abstracts 48 first fractures among
Page 52 and 53: product news 50 New product informa
Page 54 and 55: product news 52 Micardis (telmisart

veNTIlATIoN - Green Cross Publishing

Create successful ePaper yourself

Delete template?

Save as template?